Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) EBITDA (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed EBITDA for 9 consecutive years, with $17.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 27.99% year-over-year to $17.1 million, compared with a TTM value of $37.3 million through Dec 2025, up 20.45%, and an annual FY2025 reading of $37.3 million, up 20.45% over the prior year.
  • EBITDA was $17.1 million for Q4 2025 at Puma Biotechnology, up from $9.6 million in the prior quarter.
  • Across five years, EBITDA topped out at $22.1 million in Q3 2024 and bottomed at -$16.6 million in Q2 2021.
  • Average EBITDA over 5 years is $6.3 million, with a median of $6.7 million recorded in 2021.
  • The sharpest move saw EBITDA crashed 333.31% in 2021, then soared 684.34% in 2023.
  • Year by year, EBITDA stood at $6.7 million in 2021, then surged by 48.8% to $10.0 million in 2022, then surged by 47.74% to $14.8 million in 2023, then dropped by 9.68% to $13.4 million in 2024, then increased by 27.99% to $17.1 million in 2025.
  • Business Quant data shows EBITDA for PBYI at $17.1 million in Q4 2025, $9.6 million in Q3 2025, and $6.6 million in Q2 2025.